Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...

These stable stocks are worth $70 billion or more, have sustainable dividends and offer insulation from a tariff war.

Seven rheumatology researchers have authored a paper questioning the utility of the 2024 National Academies’ broad definition of long COVID.

Public health experts worry the FDA workforce will be slashed, impeding the ability of the agency to review new medicines ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Sysco pays $2.04 annually based on its latest 51-cent quarterly dividend payout, which translates to an approximate 2.79% yield. However, the company has been known to announce dividend hikes in April ...

As detailed in our previous updates, the IRA’s Medicare Drug Price Negotiation Program (the Negotiation Program or Program), ...

1 Ironwood’s U.S. collaborative arrangements revenue includes reimbursement from AbbVie for a portion of ... EBITDA represents an update to our definition of Adjusted EBITDA, effective in ...

Although by definition, a diagnosis of IBS cannot be made ... Competing interests JW has no conflict of interest to disclose; JS reports speaker’s fees from Pfizer, Abbvie, Ferring, Falk, Takeda, ...

Conclusions The different remission and LDA targets show us significant overlap between measures, but these measures targeting the same definition do differ in ... speakers/consultancy fees from ...

AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.82).